Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (13514)	1/20/1998 10:53:00 AM
From: Henry Niman	Respond to of 32384

I couldn't figure out if prostate and ovarian were for Panretin or Targretin. I think that drops in markers for both have been seen with Targretin, so data could be quite good.

To: Andrew H who wrote (13514)	1/20/1998 11:23:00 AM
From: Flagrante Delictu	Read Replies (4) \| Respond to of 32384

Andy, >> expectation on whether clinicals on prostate & ovarian cancer will be positive<<. At the breakout session after the LGND presentation at H&Q, Dr. Steven Reich seemed to indicate that LGND would be going forward in the areas of NSCLC, prostate, ovarian, & breast cancer. That being so, one would assume that their clinicals are at least sufficient in the eyes of the co. Maybe medsunman & Vector 1 could comment on their interpretation of what was said in this area. For their information, I was the guy who asked DR about any progress on the leptin deal, which elicited his response that if it were not done shortly with the original target, it would be brought to the fallback suitor for a presumably quick consumation {IYWPTE}. Bernie